Want to see BNGO full AI Analyst Report?
Top Page
BioNano Genomics
(NASDAQ:BNGO)
Select Model
Select Model
Rating:49Neutral
Price Target:
$1.00
▼(-20.00% Downside)
Action:Reiterated
Date:10/23/26
BNGO scores in the high-risk range primarily due to still-deep losses and ongoing cash burn despite improving margins and reduced leverage. Technicals also weigh on the score as the stock remains in a clear downtrend (below all major moving averages) even though momentum is oversold. Offsetting these is a better earnings-call outlook with a revenue beat, raised low-end guidance, record consumable demand, and improved gross margin, but near-term upside is constrained by manufacturing/backlog limits and tight liquidity.
Positive Factors
Recurring Consumables Growth
Strong consumable growth and higher utilization at existing customer sites support a more recurring revenue model than instrument sales alone. As the installed base expands, ongoing sample processing can increase revenue visibility, deepen customer retention, and improve the platform’s economic attractiveness.
Negative Factors
Persistent Cash Burn
The core business remains unable to fund itself, with substantial operating and free-cash-flow deficits despite improvement from earlier periods. Continued cash consumption limits financial flexibility and makes future operations dependent on additional capital access, cost reductions, or a faster transition to profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring Consumables Growth
Strong consumable growth and higher utilization at existing customer sites support a more recurring revenue model than instrument sales alone. As the installed base expands, ongoing sample processing can increase revenue visibility, deepen customer retention, and improve the platform’s economic attractiveness.
Read all positive factors
BioNano Genomics Key Performance Indicators (KPIs)
Any
Revenue by Segment
Shows how much revenue each business segment generates, highlighting which areas drive growth and which may need strategic adjustments.
Shows how much revenue each business segment generates, highlighting which areas drive growth and which may need strategic adjustments.
Data provided by:
The Fly
The FlyBioNano Genomics (BNGO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$14.37M
Dividend YieldN/A
Average Volume (3M)1.85M
Price to Earnings (P/E)―
Beta (1Y)1.36
Revenue Growth10.03%
EPS Growth91.68%
CountryUS
Employees96
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-3.73
Shares Outstanding11,777,000
10 Day Avg. Volume249,824
30 Day Avg. Volume1,850,044
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.19
Price to Sales (P/S)0.29
P/FCF Ratio-0.51
Enterprise Value/Market Cap0.65
Enterprise Value/Revenue0.31
Enterprise Value/Gross Profit0.65
Enterprise Value/Ebitda-0.42
Forecast
1Y Price Target
$4.00Price Target Upside220.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.13
Revenue Forecast (FY)$32.14M
BioNano Genomics Business Overview & Revenue Model
Company Description
Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome usin...
How the Company Makes Money
BioNano Genomics primarily generates revenue through a tools-and-consumables model tied to its optical genome mapping platform. Key revenue streams include: (1) Instrument/system sales: revenue from selling OGM instruments (e.g., the Saphyr system...
BioNano Genomics Earnings Call Summary
Earnings Call Date:Aug 10, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 10, 2026
Earnings Call Sentiment Positive
The call conveyed strong execution on key commercial and clinical fronts: double-digit revenue growth, record flow-cell sales, a shift to higher-margin consumable revenue, improved gross margins (53%), significant clinical publications validating OGM, and the retirement of convertible debt. These positives were tempered by operational constraints — notably manufacturing capacity and backorders — a modest cash balance with runway into early 2027, and a YoY decline in software revenue. Management raised the low end of full-year guidance but remained cautious on the upside until supply constraints are resolved.Positive Updates
Revenue Growth and Beat
Total revenue of $8.2 million in Q2 2026, up 21% year-over-year, and above prior guidance of $7.5M–$7.8M.
Negative Updates
Manufacturing Capacity Constraints and Backlog
Consumable demand continues to outpace current manufacturing capacity, creating backorders and limiting management's willingness to raise the upper end of revenue guidance; supply constraints cited as the primary reason for conservative near-term outlook.
Read all updates
Q2-2026 Updates
Positive
Negative
Revenue Growth and Beat
Total revenue of $8.2 million in Q2 2026, up 21% year-over-year, and above prior guidance of $7.5M–$7.8M.
Read all positive updates
Company Guidance
Bionano raised the low end of its full‑year 2026 revenue guidance to $31.0M–$33.0M (up ~9%–16% vs. 2025) and initiated Q3 guidance of $8.2M–$8.6M (up ~11%–16% vs. Q3 2025) after reporting Q2 revenue of $8.2M (up 21% YoY and above prior guidance of $7.5M–$7.8M), selling 9.22k flow cells (up 27% YoY), delivering a record adjusted gross margin of 53%, recording adjusted operating expense of $8.7M, ending the quarter with $10.4M in cash/short‑term securities (including $0.5M restricted) and a cash runway into at least Q1 2027, and noting full retirement of its senior secured convertible debt — while management cautioned they kept the upside conservative due to flow‑cell manufacturing constraints, backlog and several large orders that could slip.BioNano Genomics Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
58
Neutral
Cash Flow
26
Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 30.18M | 28.51M | 30.78M | 36.12M | 27.80M | 17.98M |
| Gross Profit | 14.34M | 6.26M | 380.00K | 9.57M | 5.95M | 3.87M |
| EBITDA | -22.41M | -16.30M | -97.47M | -213.60M | -120.79M | -73.86M |
| Net Income | -32.16M | -26.39M | -112.02M | -232.49M | -132.60M | -72.44M |
Balance Sheet | ||||||
| Total Assets | 47.59M | 73.58M | 76.67M | 214.40M | 307.50M | 377.10M |
| Cash, Cash Equivalents and Short-Term Investments | 9.92M | 13.26M | 9.47M | 66.77M | 113.19M | 250.61M |
| Total Debt | 6.70M | 6.92M | 27.30M | 79.41M | 11.67M | 10.70M |
| Total Liabilities | 15.98M | 29.16M | 41.30M | 118.25M | 58.10M | 39.98M |
| Stockholders Equity | 31.61M | 44.42M | 35.38M | 96.16M | 249.40M | 337.12M |
Cash Flow | ||||||
| Free Cash Flow | -20.48M | -16.34M | -69.03M | -126.87M | -128.12M | -73.39M |
| Operating Cash Flow | -20.48M | -16.34M | -68.92M | -125.18M | -124.82M | -71.93M |
| Investing Cash Flow | 18.48M | -12.75M | 73.84M | 24.16M | 82.77M | -278.06M |
| Financing Cash Flow | 2.64M | 24.04M | -13.69M | 113.81M | 23.01M | 336.11M |
BioNano Genomics Technical Analysis
Negative
1.25
Price Trends
1.38
Negative
1.26
Negative
1.25
Negative
Market Momentum
-0.08
Positive
39.66
Neutral
22.74
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BNGO, the sentiment is Negative. The current price of 1.25 is below the 20-day moving average (MA) of 1.35, below the 50-day MA of 1.38, and above the 200-day MA of 1.25, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 39.66 is Neutral, neither overbought nor oversold. The STOCH value of 22.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BNGO.
BioNano Genomics Risk Analysis
BioNano Genomics disclosed 83 risk factors in its most recent earnings report. BioNano Genomics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BioNano Genomics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $231.60M | -6.92 | -788.19% | ― | 34.46% | 43.48% | |
53 Neutral | $601.64M | -5.26 | -32.59% | 13.45% | -3.16% | 72.02% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $1.73B | -14.66 | -46.47% | ― | -13.26% | 14.26% | |
49 Neutral | $14.37M | -0.33 | -78.78% | ― | 10.03% | 91.68% | |
48 Neutral | $569.57M | -7.34 | -7.87% | ― | 6.83% | -69.59% | |
47 Neutral | $124.85M | -1.23 | -12.97% | ― | -3.65% | 51.30% |
* Healthcare Sector Average
BNGO
BioNano Genomics
1.22
-0.65
-34.76%
MYGN
Myriad Genetics
6.29
-1.84
-22.63%
FLGT
Fulgent Genetics
20.70
-2.73
-11.65%
PSNL
Personalis
15.98
6.23
63.90%
BNR
Burning Rock Biotech
11.87
-0.39
-3.18%
BDSX
Biodesix
21.95
15.40
235.11%
BioNano Genomics Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
BioNano Genomics Highlights Optical Genome Mapping Strategy
Positive
Sep 14, 2026
On September 14, 2026, Chairman and Interim CEO Albert Luderer presented Bionano Genomics’ strategy and technology at the H.C. Wainwright 28th Annual Global Investment Conference, highlighting the clinical transition and growing adoption of ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.